AstraZeneca lung cancer drug Tagrisso approved by EU regulators - Sharecast.com
AstraZeneca's Tagrisso approved by EU regulators for EGFR-mutated NSCLC, reducing disease progression risk by 84% in LAURA trial. This marks the fifth major approval globally, with applications under review in China, Japan, and others.
Highlighted Terms
Related News
AstraZeneca lung cancer drug Tagrisso approved by EU regulators - Sharecast.com
AstraZeneca's Tagrisso approved by EU regulators for EGFR-mutated NSCLC, reducing disease progression risk by 84% in LAURA trial. This marks the fifth major approval globally, with applications under review in China, Japan, and others.